OPEN ACCESS Freely available online

ISSN: 2155-6121
Journal of
Allergy & Therapy

Commentary

The Role of Biologics in Severe Asthma Management: Current Evidence and Clinical Applications

Annemarie Peroni*

Department of Health, University of Paris, Paris, France

DESCRIPTION

The management of severe asthma has revolutionized by the introduction of biological therapies targeting specific inflammatory pathways. This article examines the current area of biological agents and their impact on severe asthma treatment paradigms. Severe asthma, a chronic inflammatory condition of the airways, presents significant challenges in management, particularly for patients who do not respond to conventional treatments like corticosteroids. In recent years, biologics have revolutionized the management of severe asthma, providing targeted therapies that address the underlying pathophysiological mechanisms. These biologics, which include monoclonal antibodies, are designed to modulate specific immune pathways, such as those involving interleukins and IgE, which are central to the inflammation seen in asthma. For patients with eosinophilic or allergic asthma, biologics have shown considerable efficacy in reducing exacerbations, improving lung function and decreasing the need for oral steroids.

This treatment approach provides a more personalized and effective solution for patients with severe asthma who experience frequent exacerbations despite standard therapy. Current evidence supports the use of biologics like omalizumab, mepolizumab, benralizumab and dupilumab, each targeting different inflammatory pathways. These therapies not only improve clinical outcomes but also enhance the quality of life for patients. However, challenges such as high costs, accessibility and long-term safety remain. This review aims to explore the current evidence surrounding biologics in severe asthma management, examining their clinical applications, safety and potential future developments in asthma care. The emergence of monoclonal antibodies targeting key inflammatory mediators has transformed severe asthma management. Anti-IgE, anti-IL-5, anti-IL-4/13 and anti-TSLP therapies have demonstrated significant efficacy in reducing exacerbations and improving lung function. These biologics provide targeted intervention for specific asthma endotypes, moving beyond traditional broad-spectrum approaches.

Biological agents in severe asthma target specific components of the inflammatory cascade. Anti-IgE therapy neutralizes circulating IgE, preventing mast cell and basophil activation. IL-5 inhibitors reduce eosinophil production and survival, while dual IL-4/13 blockade affects multiple aspects of type 2 inflammation. Understanding these mechanisms has led to precise patient selection strategies. Recent phase III trials have demonstrated substantial reductions in exacerbation rates, ranging from 50% to 70% across different biologics. Improvements in FEV1, symptom scores and quality of life measures have consistently reported. Long-term extension studies suggest sustained efficacy with favorable safety profiles extending beyond five years of treatment. The identification of reliable biomarkers has become essential for appropriate patient selection. Blood eosinophil counts, serum IgE levels and FeNO measurements guide therapy selection. Recent advances in transcriptomics and proteomics have revealed additional biomarkers that may further refine patient stratification. The safety profile of biological agents remains favorable, with injection site reactions being the most common adverse event. Anaphylaxis occurs rarely, affecting less than 1% of treated patients. Long-term safety data continue to accumulate, supporting the positive benefit-risk ratio of these interventions.

Economic analyses indicate significant costs associated with biological therapies. However, reductions in hospitalization rates, emergency department visits and oral corticosteroid use offset some expenses. Healthcare systems increasingly recognize the value proposition of these interventions for appropriate patients. The pipeline of biological therapies continues to expand with novel targets under investigation. Combination approaches and alternative delivery systems may further enhance therapeutic options. The integration of artificial intelligence in patient selection may optimize treatment outcomes.

In conclusion, biological therapies represent a significant advancement in severe asthma management. Continued refinement of patient selection criteria and accumulating long-term data will further establish their role in clinical practice.

Correspondence to: Annemarie Peroni, Department of Health, University of Paris, Paris, France, E-mail: anneperoni@edu.fr

Received: 30-Aug-2024, Manuscript No. JAT-24-27990; **Editor assigned:** 02-Sep-2024, PreQC No. JAT-24-27990 (PQ); **Reviewed:** 16-Sep-2024, QC No. JAT-24-27990; **Revised:** 23-Sep-2024, Manuscript No. JAT-24-27990 (R); **Published:** 30-Sep-2024, DOI: 10.35248/2155-6121.24.15.399

Citation: Peroni A (2024). The Role of Biologics in Severe Asthma Management: Current Evidence and Clinical Applications. J Allergy Ther. 15:399.

Biological therapies have significantly transformed the management of severe asthma, providing a targeted approach that addresses the underlying inflammatory mechanisms responsible for the disease. These therapies have demonstrated considerable efficacy in reducing exacerbations, improving lung function and enhancing the quality of life for patients, particularly those with eosinophilic or allergic asthma. While challenges such as cost, accessibility and long-term safety remain, the evidence supporting their use is robust, with favorable outcomes reported across multiple clinical trials. Ongoing advancements in biomarker identification, patient selection and the development of novel therapies suggest that the future of severe asthma treatment is poised for further improvement.